Drug intelligence / Profile preview

NPL-102

Development stage: Preclinical
Lead developer: Novatek Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

NPL-102 is a biosimilar monoclonal antibody candidate developed by Novatek Pharmaceuticals. It is designed to target the Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), an immune checkpoint receptor that functions as a negative regulator of T-cell activation. By binding to CTLA-4, NPL-102 prevents its interaction with ligands CD80 and CD86 on antigen-presenting cells, thereby maintaining T-cell activity and enhancing the immune system's ability to recognize and destroy malignant cells. It is being developed for multiple oncology indications as a biosimilar to the reference product ipilimumab.

Other names: NPL-102NPL102NPL 102

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on NPL-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NPL-102.

Explore the full profile